Pharma R&D has to be collaborative, says Tufts Center

The Center claimed that the pace and development of pharmaceutical companies in the future would largely depend on strategic alliances and partnerships they forge in their R&D activities. The Center also reported findings from a research study that found correlation between organizations with centralized decision-making structures and higher levels of R&D efficiency.

Kenneth Kaitin, director of CSDD, said: “Increasingly, R&D productivity gains will depend on developers focusing on what they contribute best to the drug development value chain and partnering with organizations that provide capabilities that are too expensive to develop or maintain internally, or are outside of the company’s core competence.”